Evidence mapPaperPMID 42421131Full record

ArticleChinese medicine2026

Resveratrol-activated PI3K/AKT/mTOR signaling pathway attenuates ferroptosis by promoting NRF2/GPX4 metabolic pathway to mitigate IFN-gamma-mediated aplastic anemia.

Erhao Zhang, Jianan Cui, Xinran Zhu, Juan Chen, Liqin Xu, Xiaomin Li, Yufei Zhang, Hui Jia, Xiaorong Zhou, Zenghua Lin and 2 more

Abstract read
In one paragraph

Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Erhao ZhangDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China. zhangerhao@ntu.edu.cn.
Jianan CuiDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China.
Xinran ZhuDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China.
Juan ChenDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China.
Liqin XuDepartment of Pulmonary and Critical Care Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China.
Xiaomin LiDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China.
Yufei ZhangDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China.
Hui JiaDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China.
Xiaorong ZhouDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China.
Zenghua LinDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China. linzenghua@126.com.
Han WangDepartment of General Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China. wwhh1991@aliyun.com.
Hong LiuDepartment of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China. hongliu63@126.com.

Funding

China Postdoctoral Science Foundation Funded Project 2022M711722Clinical Medicine Research Project of Nantong University 2024LZ026grants from Jiangsu Provincial Research Hospital YJXYY202204grants from the Nantong Health Commission Project QN2023007National Natural Science Foundation of China 81903154
6 · The paper itself

Abstract

backgroundAplastic anemia (AA) is a severe hematological disorder caused by hyperactivated T cell-mediated hematopoietic failure. It is characterized by hematopoietic stem cell deficiency and hypocellular hematopoiesis in the bone marrow (BM). Ferroptosis, a specific type of programmed cell death, is defined by iron-dependent lipid peroxidation, which has garnered the attention of researchers due to its unique role and biological importance in various diseases. However, the correlation between immunological imbalance-induced ferroptosis and the mortality of hematopoietic stem cells within the BM microenvironment in AA is unclear. Resveratrol (RSV) is crucial in activating NRF2, hence influencing the onset and progression of diseases by regulating ferroptosis. This study aimed to investigate the roles and molecular mechanisms of RSV in the hematopoietic recovery of AA regarding ferroptosis.

methodsWe measured some biomarkers in AA mice and IFN-gamma-treated 32D cells, representing AA syndromes and ferroptosis features. Furthermore, in RSV-treated 32D AA cells, cell activity, cell apoptosis, mitochondrial membrane potential, mitochondrial membrane permeability, and intracellular levels of MDA, ferrous iron, 4-HNE, GSH, ROS, and lipid peroxidation were assessed. Subsequently, additional in vitro and in vivo experiments were performed to investigate the mechanisms by which RSV effectively regulates NRF2 stability, further inhibiting ferroptosis in AA.

resultsWe demonstrated that ferroptosis contributes to the occurrence and development of AA disease. RSV dose-dependently inhibits ferroptosis in 32D AA cells by targeting GPX4 expression, enhancing the cell activity of hematopoietic BM cells. Mechanically, RSV significantly increases NRF2 phosphorylation through the PI3K/AKT/mTOR signaling pathway, which maintains NRF2 stability to promote the GPX4 metabolic pathway in AA. Protein levels of p-AKT, p-mTOR, p-NRF2, and GPX4 were markedly increased in BM cells in RSV-treated AA mice, resulting in the suppression of AA development.

conclusionOur data demonstrate that RSV effectively inhibits ferroptosis in AA or IFN-gamma-treated 32D cells by targeting the PI3K/AKT/mTOR signaling pathway, which enhances NRF2-mediated GPX4 transcription, thereby ameliorating AA symptoms in vitro and in vivo. This study concludes that RSV is a potential therapeutic drug for ferroptosis-related AA treatment.

Indexed as

Aplastic anemiaFerroptosisGPX4NRF2Resveratrol

Identifiers

PMID42421131
PMCPMC13343987

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.